Pathogenesis analysis of pituitary adenoma based on gene expression profiling

Oncology Letters

Volumn 8, Issue 6, 2014, Pages 2423-2430

  Wang, Weimin ^a,b   Xu, Zhiming ^b   Fu, Li ^b   Liu, Wei ^b   Li, Xingang ^a,c  

^a SHANDONG UNIVERSITY   (China)

^b QINGDAO MUNICIPAL HOSPITAL   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Differentially expressed genes; Interleukin 6; Pituitary adenoma; POU1F1; Signal transducer and activator of transcription 3

Indexed keywords

EARLY GROWTH RESPONSE FACTOR 1; HYPOPHYSIS HORMONE; INTERLEUKIN 6; MESSENGER RNA; PROTEIN BCL 6; PROTEIN C JUN; PROTEIN FOS; STAT3 PROTEIN; THYROTROPIN; TRANSCRIPTION FACTOR PIT 1;

ARTICLE; CELL PROLIFERATION; FUNCTIONAL GENOMICS; GENE EXPRESSION; GENE ONTOLOGY; GENETIC SCREENING; HORMONAL REGULATION; HUMAN; HYPOPHYSIS ADENOMA; IMMUNE RESPONSE; PATHOGENESIS; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 84908053769     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2613     Document Type: Article

References (46)

1. Woods KS, Cundall M, Turton J, et al: Over-and underdosage of SOX3 is associated with infundibular hypoplasia and hypopituitarism. Am J Hum Genet 76: 833-849, 2005.
2. Suhardja A, Kovacs K and Rutka J: Role of transcription factors in the pathogenesis of pituitary adenomas: a review. J Neurooncol 55: 185-193, 2001.
3. Burrows HL, Douglas KR, Seasholtz AF and Camper SA: Genealogy of the anterior pituitary gland: tracing a family tree. Trends Endocrinol Metab 10: 343-352, 1999.
4. Gold PW, Gwirtsman H, Avgerinos PC, et al: Abnormal hypothalamic-pituitary-adrenal function in anorexia nervosa. Pathophysiologic mechanisma in underweight and weight-corrected patients. N Engl J Med 314: 1335-1342, 1986.
5. Asa SL and Ezzat S: Genetics and proteomics of pituitary tumors. Endocrine 28: 43-47, 2005.
6. Castinetti F, Reynaud R, Saveanu A, et al: Clinical and genetic aspects of combined pituitary hormone deficiencies. Ann Endocrinol (Paris) 69: 7-17, 2008 (in French).
7. Davis SW, Castinetti F, Carvalho LR, et al: Molecular mechanisms of pituitary organogenesis: In search of novel regulatory genes. Mol Cell Endocrinol 323: 4-19, 2010.
8. Ezzat S, Asa SL, Couldwell WT, et al: The prevalence of pituitary adenomas: a systematic review. Cancer 101: 613-619, 2004.
9. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA and Beckers A: High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocr Metab 91: 4769-4775, 2006.
10. Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature 408: 307-310, 2000.
11. Michaelis KA, Knox AJ, Xu M, et al: Identification of growth arrest and DNA-damage-inducible gene beta (GADD45 beta) as a novel tumor suppressor in pituitary gonadotrope tumors. Endocrinology 152: 3603-3613, 2011.
12. Sánchez-Tejada L, Sánchez-Ortiga R, Moreno-Pérez Ó, et al: Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness. Endocrinol Nutr 60: 358-367, 2013.
13. D'Angelo D, Palmieri D, Mussnich P, et al: Altered microRNA expression profile in human pituitary GH adenomas: down-regulation of miRNA targeting HMGA1, HMGA2, and E2F1. J Clin Endocrinol Metab 97: E1128-E1138, 2012.
14. Yacqub-Usman K, Richardson A, Duong CV, et al: The pituitary tumour epigenome: aberrations and prospects for targeted therapy. Nat Rev Endocrinol 8: 486-494, 2012.
15. Gautier L, Cope L, Bolstad BM and Irizarry RA: affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20: 307-315, 2004.
16. Durinck S, Spellman PT, Birney E and Huber W: Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. Nat Protoc 4: 1184-1191, 2009.
17. Dennis G Jr, Sherman BT, Hosack DA, et al: DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: P3, 2003.
18. Cabin RJ and Mitchell RJ: To Bonferroni or not to Bonferroni: when and how are the questions. ESA Bull 81: 246-248, 2000.
19. Jensen LJ, Kuhn M, Stark M, et al: STRING 8 - a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res 37: D412-D416, 2009.
20. Liu ZP, Wang Y, Zhang XS and Chen L: Identifying dysfunctional crosstalk of pathways in various regions of Alzheimer's disease brains. BMC Syst Biol 4: S11, 2010.
21. Matys V, Fricke E, Geffers R, et al: TRANSFAC: transcriptional regulation, from patterns to profiles. Nucleic Acids Res 31: 374-378, 2003.
22. Smoot ME, Ono K, Ruscheinski J, Wang PL and Ideker T: Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 27: 431-432, 2011.
23. Hu Y, Chen H, Duan C, et al: Deficiency of Erbin induces resistance of cervical cancer cells to anoikis in a STAT3-dependent manner. Oncogenesis 2: e52, 2013.
24. Lan XY, Pan CY, Chen H, et al: An AluI PCR-RFLP detecting a silent allele at the goat POU1F1 locus and its association with production traits. Small Rumin Res 73: 8-12, 2007.
25. Carlomagno Y, Salerno M, Vivenza D, et al: A novel recessive splicing mutation in the POU1F1 gene causing combined pituitary hormone deficiency. J Endocrinol Invest 32: 653-658, 2009.
26. Turton JP, Strom M, Langham S, Dattani MT and Le Tissier P: Two novel mutations in the POU1F1 gene generate null alleles through different mechanisms leading to combined pituitary hormone deficiency. Clin Endocrinol (Oxf) 76: 387-393, 2012.
27. Tenenbaum-Rakover Y, Sobrier ML and Amselem S: A novel POU1F1 mutation (p.Thr168IlefsX7) associated with an early and severe form of combined pituitary hormone deficiency: functional analysis and follow-up from infancy to adulthood. Clinical Endocrinol (Oxf) 75: 214-219, 2011.
28. Reynaud R, Castinetti F, Galon-Faure N, et al: Genetic aspects of growth hormone deficiency. Arch Pediatr 18: 696-706, 2011 (In French).
29. Zhong Z, Wen Z and Darnell JE Jr: Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264: 95-98, 1994.
30. Borg SA, Kerry KE, Royds JA, Battersby RD and Jones TH: Correlation of VEGF production with IL1 alpha and IL6 secretion by human pituitary adenoma cells. Eur J Endocrinol 152: 293-300, 2005.
31. Jones TH, Justice S, Price A and Chapman K: Interleukin-6 secreting human pituitary adenomas in vitro. J Clin Endocrinol Metab 73: 207-209, 1991.
32. Jones TH, Daniels M, James RA, et al: Production of bioactive and immunoreactive interleukin-6 (IL-6) and expression of IL-6 messenger ribonucleic acid by human pituitary adenomas. J Clin Endocrinol Metab 78: 180-187, 1994.
33. Green VL, Atkin SL, Speirs V, et al: Cytokine expression in human anterior pituitary adenomas. Clin Endocrinol (Oxf) 45: 179-185, 1996.
34. Vankelecom H, Carmeliet P, Van Damme J, Billiau A and Denef C: Production of interleukin-6 by folliculo-stellate cells of the anterior pituitary gland in a histiotypic cell aggregate culture system. Neuroendocrinology 49: 102-106, 1989.
35. Ueta Y, Levy A, Chowdrey HS and Lightman SL: S-100 antigen-positive folliculostellate cells are not the source of IL-6 gene expression in human pituitary adenomas. J Neuroendocrinol 7: 467-474, 1995.
36. Gaïni S, Koldkjær OG, Pedersen C and Pedersen SS: Procalcitonin, lipopolysaccharide-binding protein, interleukin-6 and C-reactive protein in community-acquired infections and sepsis: a prospective study. Crit Care 10: R53, 2006.
37. Sutherland RE, Olsen JS, Mckinstry A, Villalta SA and Wolters PJ: Mast cell IL-6 improves survival from Klebsiella pneumonia and sepsis by enhancing neutrophil killing. J Immunol 181: 5598-5605, 2008.
38. Matsukawa A, Takeda K, Kudo S, Maeda T, Kagayama M and Akira S: Aberrant inflammation and lethality to septic peritonitis in mice lacking STAT3 in macrophages and neutrophils. J Immunol 171: 6198-6205, 2003.
39. Darnell JE, Jr: STATs and gene regulation. Science 277: 1630-1635, 1997.
40. Song JI and Grandis JR: STAT signaling in head and neck cancer. Oncogene 19: 2489-2495, 2000.
41. Scholz A, Heinze S, Detjen KM, et al: Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology 125: 891-905, 2003.
42. Page C, Huang M, Changery J, et al: Expression of constitutive activation of AKT and Stat3 oncogene products in ovarian, cervical, and prostate cancer cells. Proceedings of the American Association for Cancer Research Annual Meeting:728-729, 2000.
43. Bowman T, Garcia R, Turkson J and Jove R: STATs in oncogenesis. Oncogene 19: 2474-2488, 2000.
44. Kusaba T, Nakayama T, Yamazumi K, et al: Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol 58: 833-838, 2005.
45. Lee CK, Raz R, Gimeno R, et al: STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. Immunity 17: 63-72, 2002.
46. Arguni E, Arima M, Tsuruoka N, Sakamoto A, Hatano M and Tokuhisa T: JunD/AP-1 and STAT3 are the major enhancer molecules for high Bcl6 expression in germinal center B cells. Int Immunol 18: 1079-1089, 2006